Filing Flows › Comparisons › VYGR vs LENZ
Voyager Therapeutics vs Lenz Therapeutics: VYGR and LENZ compared
Voyager Therapeutics is the larger company: $4.0M of revenue in its latest quarter (Q3 2026) against $3.4M for Lenz Therapeutics (Q3 2026). Voyager Therapeutics is growing faster (-70% against -73% a year earlier). Voyager Therapeutics is more profitable, with an operating margin of -658.2% against -972.8%.
Where the money goes: VYGR and LENZ
Voyager Therapeutics (VYGR) · Q3 2026
Voyager Therapeutics, Q3 2026: revenue $4.0M (-70% year over year), operating margin -658.2%, net loss $24.7M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
Lenz Therapeutics (LENZ) · Q3 2026
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
| Voyager Therapeutics (VYGR) | Lenz Therapeutics (LENZ) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $4.0M | $3.4M |
| Revenue growth, Y/Y | -70% | -73% |
| Operating margin | -658.2% | -972.8% |
| Net earnings | −$24.7M | −$31.0M |
| Net margin | -615.2% | -915.2% |
| Operating cash flow | −$19.7M | −$22.3M |
Where the revenue comes from
Lenz Therapeutics
- Product sales, net: $2.6M (77%)
- License revenue: $785K (23%)
Questions
Which is bigger, Voyager Therapeutics or Lenz Therapeutics?
Voyager Therapeutics is the larger company: $4.0M of revenue in its latest quarter (Q3 2026) against $3.4M for Lenz Therapeutics (Q3 2026).
Is Voyager Therapeutics or Lenz Therapeutics growing faster?
Voyager Therapeutics is growing faster (-70% against -73% a year earlier).
Which is more profitable, Voyager Therapeutics or Lenz Therapeutics?
Voyager Therapeutics is more profitable, with an operating margin of -658.2% against -972.8%.
More: Voyager Therapeutics earnings · how Voyager Therapeutics makes money · Lenz Therapeutics earnings · how Lenz Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.